Research programme: antibacterials - CytoGenix
Alternative Names: Antibacterials (multi-drug resistant) compound research programme - CytoGenix; CY 401; CY 403; CYGX 0401; Gene silencing antibacterial therapies - CytoGenix; RBL-1 research programme - CytoGenix/Imperial College London; Research programme: RBL1 - CytoGenix/Imperial College LondonLatest Information Update: 04 Nov 2017
At a glance
- Originator CytoGenix
- Developer CytoGenix; Imperial College of Science, Technology and Medicine
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in United Kingdom
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in USA
- 09 Aug 2005 CytoGenix and Imperial College London have entered into an agreement to co-develop RBL1